Tout DSpace

Afficher la notice abrégée

Checkpoint modulation in chronic hepatitis B: From hypothesis to approval

dc.creatorGermanidis G., Hytiroglou P., Vassiliadis T., Speletas M.en
dc.date.accessioned2023-01-31T07:41:08Z
dc.date.available2023-01-31T07:41:08Z
dc.date.issued2018
dc.identifier10.1002/hep.29695
dc.identifier.issn02709139
dc.identifier.urihttp://hdl.handle.net/11615/72209
dc.description.abstract[No abstract available]en
dc.language.isoenen
dc.sourceHepatologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85041206351&doi=10.1002%2fhep.29695&partnerID=40&md5=078fe8ac094b1fe9938f7abbc1db5ff0
dc.subjectCD8 antigenen
dc.subjectcytotoxic T lymphocyte antigen 4en
dc.subjectFas liganden
dc.subjectinterleukin 10en
dc.subjectmessenger RNAen
dc.subjecttranscription factor 7en
dc.subjecttranscription factor FOXP3en
dc.subjecttransforming growth factor beta1en
dc.subjectantivirus agenten
dc.subjectantiviral therapyen
dc.subjectCD8+ T lymphocyteen
dc.subjectchronic hepatitis Ben
dc.subjectclinical practiceen
dc.subjecteffector cellen
dc.subjectgermline mutationen
dc.subjecthaploinsufficiencyen
dc.subjectheterozygoteen
dc.subjecthumanen
dc.subjectimmune dysregulationen
dc.subjectLetteren
dc.subjectpriority journalen
dc.subjectregulatory T lymphocyteen
dc.subjectremissionen
dc.subjectT lymphocyte subpopulationen
dc.subjectdrug approvalen
dc.subjecthepatitis Ben
dc.subjectAntiviral Agentsen
dc.subjectDrug Approvalen
dc.subjectHepatitis Ben
dc.subjectHepatitis B, Chronicen
dc.subjectHumansen
dc.subjectJohn Wiley and Sons Inc.en
dc.titleCheckpoint modulation in chronic hepatitis B: From hypothesis to approvalen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée